<?xml version='1.0'?>
<!DOCTYPE art SYSTEM 'http://www.biomedcentral.com/xml/article.dtd'>
<art>
   <ui>ar1633</ui>
   <ji>ARJ</ji>
   <fm>
      <dochead>Poster presentation</dochead>
      <bibl>
         <title>
            <p>Requirement of IL-17 receptor signaling in resident synoviocytes for development of full blown destructive arthritis</p>
         </title>
         <aug>
            <au id="A1">
               <snm>Lubberts</snm>
               <fnm>E</fnm>
               <insr iid="I1"/>
               <insr iid="I2"/>
            </au>
            <au id="A2">
               <snm>Schwarzenberger</snm>
               <fnm>P</fnm>
               <insr iid="I2"/>
            </au>
            <au id="A3">
               <snm>Huang</snm>
               <fnm>W</fnm>
               <insr iid="I2"/>
            </au>
            <au id="A4">
               <snm>Schurr</snm>
               <fnm>JR</fnm>
               <insr iid="I2"/>
            </au>
            <au id="A5">
               <snm>Peschon</snm>
               <fnm>JJ</fnm>
               <insr iid="I3"/>
            </au>
            <au id="A6">
               <snm>van den Berg</snm>
               <fnm>WB</fnm>
               <insr iid="I1"/>
            </au>
            <au id="A7">
               <snm>Kolls</snm>
               <fnm>JK</fnm>
               <insr iid="I2"/>
            </au>
         </aug>
         <insg>
            <ins id="I1">
               <p>University Medical Center St Radboud, Department of Rheumatology, Nijmegen, The Netherlands</p>
            </ins>
            <ins id="I2">
               <p>LSU Health Sciences Center, Department of Medicine, Gene Therapy Program, New Orleans, Louisiana, USA</p>
            </ins>
            <ins id="I3">
               <p>Amgen, Seattle, Washington, USA</p>
            </ins>
         </insg>
         <source>Arthritis Research &amp; Therapy</source>
         <supplement>
            <title>
               <p>25<sup>th</sup> European Workshop for Rheumatology Research</p>
            </title>
            <sponsor>
               <note>The organizer would like to thank the following companies who have generously supported the meeting: Abbott Immunology (Main sponsor), Bristol-Myers Squibb, Schering-Plough, Wyeth, AstraZeneca, MSD, Amgen</note>
            </sponsor>
            <note>Meeting abstracts</note>
         </supplement>
         <conference>
            <title>
               <p>25<sup>th</sup> European Workshop for Rheumatology Research</p>
            </title>
            <location>Glasgow, UK</location>
            <date-range>24-27 February 2005</date-range>
         </conference>
         <issn>1478-6354</issn>
         <pubdate>2005</pubdate>
         <volume>7</volume>
         <issue>Suppl 1</issue>
         <fpage>P112</fpage>
         <xrefbib>
            <pubid idtype="doi">10.1186/ar1633</pubid>
         </xrefbib>
      </bibl>
      <history>
         <rec>
            <date>
               <day>11</day>
               <month>1</month>
               <year>2005</year>
            </date>
         </rec>
         <pub>
            <date>
               <day>17</day>
               <month>2</month>
               <year>2005</year>
            </date>
         </pub>
      </history>
      <cpyrt>
         <year>2005</year>
         <collab>BioMed Central Ltd</collab>
      </cpyrt>
   </fm>
   <bdy>
      <sec>
         <st>
            <p/>
         </st>
         <p>Chronic arthritis is characterized by persistent joint inflammation and concomitant joint destruction. IL-17 is a novel proinflammatory T-cell cytokine suspected to be involved in inflammatory and autoimmune diseases such as rheumatoid arthritis. Here, we report that IL-17 receptor (IL-17R) signaling is required in resident synovial cells for full progression of chronic synovitis and bone erosion. Repeated injections of Gram-positive bacterial cell wall fragments (SCW) directly into the knee joint of na&#239;ve IL-17R-deficient (IL-17R<sup>-/-</sup>) mice had no effect on the acute phase of arthritis but prevented progression to chronic destructive synovitis as was noted in wild-type (wt) mice. Micro-array analysis revealed significant down-regulation of leukocyte-specific chemokines, selectins, collagenase-3, and IL-1 in the synovium of IL-17R<sup>-/- </sup>mice. Bone marrow (BM) chimeric mice revealed the need for IL-17/IL-17R signaling in resident synovial cells for development of full blown synovitis. Chimeric mice of host wt and donor IL-17R<sup>-/- </sup>BM cells developed destructive synovitis in this chronic relapsing SCW arthritis model similar to wt &#8594; wt chimeras. In contrast, chimeric mice of host IL-17R<sup>-/- </sup>and donor wt BM cells were protected from full blown destructive arthritis similar to IL-17R<sup>-/- </sup>&#8594; IL-17R<sup>-/- </sup>chimeras. These data strongly suggest T-cell IL-17-IL-17R signaling in resident synovial cells to be a pivotal mechanism through which an acute macrophage-driven joint inflammation progresses into a chronic destructive synovitis. Prevention of local synovial IL-17-IL-17R signaling warrants consideration as a therapeutic target in chronic destructive arthritis.</p>
      </sec>
   </bdy>
</art>
